ClinicalTrials.gg
TerminatedNCT05636267Updated Mar 9, 2026

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

A Phase 1/2 interventional study of AK119 and AK112 in NSCLC, sponsored by Akeso. Terminated at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Terminated due to sponsor strategic development reprioritization.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and voluntarily sign the written , which must be signed before the designated research procedure.
  2. Age ≥ 18 and ≤ 75, male or female.
  3. Local advanced or non-squamous NSCLC confirmed by histology or cytology according to eighth edition of the TNM classification for lung cancer.
  4. EGFR activating mutation confirmed by tumor histology, cytology or hematology.
  5. Failed to previous EGFR-TKI treatment.
  6. performance status 0 to1.
  7. ≥3 months.
  8. At least one according to v1.1.
  9. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Histological or cytological pathology confirmed the presence of small cell carcinoma or squamous cell carcinoma.
  2. Have suffered from the second primary active malignant tumor in the past 3 years.
  3. There are other driving gene mutations that can obtain effective treatment.
  4. Receipt of the following treatments or procedures: immunotherapy, including immunocheckpoint inhibitors, immunocheckpoint agonists, immunocellular therapy, and any other treatment targeting tumor immune mechanism; systematic chemotherapy in the advanced stage (IIIB-IV); anti-angiogenesis drugs, except for small molecule anti-angiogenesis drugs with drug withdrawal more than 4 weeks; extensive radiotherapy within 4 weeks; EGFR-TKIs within 2 weeks.
  5. Symptomatic central nervous system .
  6. The toxicity of previous anti-tumor therapy has not been alleviated.
  7. Uncontrolled massive ascites, pleural effusion or pericardial effusion.
  8. Active diseases in the past 2 years.
  9. History of interstitial lung disease or noninfectious pneumonitis.
  10. Suffering from cardiovascular or cerebrovascular diseases.
  11. History of severe bleeding tendency or coagulation dysfunction.
  12. History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism in the past 3 months.
  13. Serious infection in the past 4 weeks.
  14. Acute exacerbation of or asthma in the past 4 weeks.
  15. History of (HIV) infection.
  16. History of severe reactions to other mAbs.
  17. History of organ transplantation.
  18. Any other conditions that, in the opinion of the investigator, may increase the risk when receiving the product.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    AK119 + AK112

    Subjects will receive AK119 plus AK112 via intravenously (IV) Q3W, up to 2 years.

    Drug: AK119 · Drug: AK112

  • Experimental
    AK119 + AK112 + Pemetrexed + Carboplatin

    Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W, up to 4 cycles. Afterward, AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.

    Drug: AK119 · Drug: AK112 · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    AK112

    Subjects will receive AK112 monotherapy via intravenously (IV) Q3W, up to 2 years.

    Drug: AK112

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with dose limiting toxicities (DLTs)

    DLTs will be assessed during the first 3 weeks of treatment. DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT observation period.

    Time frame: During the first 3 weeks

  2. Number of subjects with adverse events (AEs)

    AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 90 days after the last dose of study drug

  3. Objective response rate (ORR)

    ORR is defined as the proportion of subjects with confirmed CR or confirmed PR.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).

    Time frame: Up to 2 years

  3. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  4. Time to response (TTR)

    TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).

    Time frame: Up to 2 years

  5. Overall survival (OS)

    OS defined as the time from the first dose to death from any cause.

    Time frame: Up to 2 years

  6. Maximum observed concentration (Cmax) of AK119 and AK112

    The PK parameters include serum concentrations of AK119 and AK112 at different timepoints after study drug administration.

    Time frame: From first dose of study drug through last dose

  7. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK119 and AK112 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).

    Time frame: From first dose of study drug through last dose

07

Study locations

1 site
  • Guangdong Provincial People's Hospital
    Guangzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Dec 5, 2022
StartActual
Feb 10, 2023
Primary completionActual
Feb 24, 2025
CompletionActual
Apr 15, 2025
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05636267
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 5, 2022
Start date
Feb 10, 2023
Primary completion
Feb 24, 2025
Completion
Apr 15, 2025
Last update
Mar 9, 2026

Study contacts

Yilong Wu, PhD
principal investigator · Guangdong Provincial People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion